As­cendis’ hy­poparathy­roidism drug sad­dled with three-month de­lay at FDA

As­cendis Phar­ma will like­ly wait three more months to get an an­swer from the FDA on the re­view of its hy­poparathy­roidism drug.

On Tues­day, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.